CHMP gives positive opinion for Novo’s Sogroya in idiopathic short stature
CHMP issued a positive opinion for Novo Nordisk’s Sogroya (somapacitan) for children with idiopathic short stature in Europe. If approved, it would be the first and only growth hormone treatment approved for this indication in the EU.